Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 12/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481934 | 0.84 | P2RX7 (0.42) | SRD5A1SRD5A2HSD17B3LMNASMN1; SMN2 | |
| SCHEMBL23957375 | 0.84 | P2RX7 (0.42) | SRD5A1SRD5A2HSD17B3LMNASMN1; SMN2 | |
| SCHEMBL4307204 | 0.81 | CYP11B2 (0.44) | SRD5A1SRD5A2KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2061217 | 0.76 | MAOA (0.52) | SRD5A1HSD17B3NOTUM | |
| SCHEMBL11263558 | 0.74 | SRD5A1 (0.55) | SRD5A1SRD5A2HSD17B3HTR2AHTR2C | |
| SCHEMBL11255201 | 0.74 | SRD5A1 (0.59) | SRD5A1SRD5A2HSD17B3KMT2ANOTUM | |
| SCHEMBL6883015 | 0.73 | MAOA (0.59) | HTR2AHTR2CHTR2B | |
| SCHEMBL2061268 | 0.72 | ATAD2 (0.50) | HSD17B3HTR2AKMT2ALMNA | |
| SCHEMBL15962624 | 0.72 | — | — | |
| SCHEMBL588130 | 0.72 | CYP2A6 (0.54) | SRD5A1SRD5A2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | SRD5A1 1381/4885SRD5A2 1266/4885HSD17B3 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.